A Study of Atezolizumab in Advanced Solid Tumors

Inclusion Criteria:

- Histologically documented advanced solid tumors that meet protocol-defined cohort
specifications, have progressive disease at study entry, and have received at least
one line of prior systemic therapy or for which no alternative therapy to prolong
survival exists

- Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin
blocks (preferred) or in freshly cut and unstained slides (exceptional cases) with an
associated pathology report for central testing

- Measurable disease as defined by RECIST v1.1 or disease-specific criteria for prostate
cancer and malignant pleural mesothelioma

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Negative serum pregnancy test result within 14 days prior to study drug among women of
childbearing potential

- Life expectancy > 3 months

Exclusion Criteria:

- Malignancies other than disease under study within 5 years prior to Day 1 of Cycle 1
except those with a negligible risk of metastasis or death

- Uncontrolled tumor-related pain

- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent
drainage procedures >/=1 time per month

- History of asymptomatic or symptomatic central nervous system (CNS) metastasis

- Leptomeningeal disease

- Spinal cord compression not definitively treated with surgery and/or radiation, or
previously diagnosed and treated but without evidence that disease has been clinically
stable for >/=2 weeks prior to Day 1 of Cycle 1

- Pregnant and lactating women

- Significant cardiovascular disease within 3 months prior to Day 1 of Cycle 1

- Severe infection within 4 weeks prior to Day 1 of Cycle 1

- Oral or IV antibiotics within 2 weeks prior to Day 1 of Cycle 1

- History of severe allergic, anaphylactic, or other hypersensitivity reactions to
chimeric or humanized antibodies or fusion proteins

- Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster
ovary cells or to any component of the atezolizumab formulation

- History of autoimmune disease except treated/stable hypothyroidism, Type 1 diabetes
mellitus, and protocol-specified dermatologic conditions

- Active tuberculosis

- Signs or symptoms of infection within 2 weeks prior to Day 1 of Cycle 1

- Prior treatment with cluster of differentiation (CD) 137 agonists or immune checkpoint
blockade therapies, or anti-programmed cell death-1 (PD-1) or anti-PD-L1 therapeutic
antibodies

- Treatment with systemic corticosteroids or other systemic immunosuppressive
medications within 2 weeks prior to Day 1 of Cycle 1, or anticipated requirement for
systemic immunosuppressive medications during the trial